Skip to main content

본문내용

종목정보

종목토론카테고리

게시판버튼

게시글 제목

휴머니젠, 텔콘,케이피엠 테크 라이센스 동의 발표

작성자 정보

대감

게시글 정보

조회 409 2021/01/20 08:29

게시글 내용

Agreement provides Humanigen up to US$20 million in milestones and double-digit royalties on product sales

  • Transaction supports the Humanigen Asia-Pacific regional corporate development strategy
  • BURLINGAME, Calif.?(BUSINESS WIRE)?Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate lenzilumab, today announced the execution of its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical, Inc. (“Telcon”) (200230.KQ) and KPM Tech Co., Ltd (“KPM Tech”) (042040.KQ) for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines.

    <img class="lazyload" src="https://mms.businesswire.com/media/20201103005167/en/835567/21/Humanigen_Logo-04.jpg">

    Telcon is an affiliate of KPM Tech and both companies recently invested in the Humanigen June 2020 PIPE offering. Telcon produces liquid formulations, tablets, pills, capsules, and other pharmaceutical products, as well as communication equipment.

    Mr. Ji-Hoon Kim, CEO of Telcon and KPM Tech, said, “We have supported Humanigen through an equity investment and see lenzilumab as an excellent therapeutic solution for the hyperinflammation seen in COVID-19 hospitalized patients. Lenzilumab has a significant part to play in the treatment of patients in the pandemic and beyond. We are honored to be sel ected to develop and potentially launch lenzilumab in South Korea and the Philippines.”

    The licensing agreement includes payments of up to US$20 million with US$6 million as an upfront payment upon execution of the licensing agreement and the balance of US$14 million in two payments based on achievement by Humanigen of specified milestones in the US. Telcon and KPM Tech will be responsible for gaining regulatory approval and subsequent commercialization of lenzilumab in its territories. Humanigen will earn double-digit royalties following receipt of those approvals on net sales subsequent to commercialization. The number of COVID-19 cases in South Korea and the Philippines is more than 412,000.1

    게시글 찬성/반대

    • 0추천
    • 0반대
    내 아이디와 비밀번호가 유출되었다? 자세히보기 →

    운영배심원의견

    운영배심원 의견?
    운영배심원의견이란
    운영배심원 의견이란?
    게시판 활동 내용에 따라 매월 새롭게 선정되는
    운영배심원(10인 이하)이 의견을 행사할 수 있습니다.

    운영배심원 4인이 글 내리기에 의견을 행사하게 되면
    해당 글의 추천수와 반대수를 비교하여 반대수가
    추천수를 넘어서는 경우에는 해당 글이 블라인드 처리
    됩니다.

    댓글목록

    댓글 작성하기

    댓글쓰기 0 / 1000

    게시판버튼

    광고영역